Numthavaj: Andrographis Paniculata vs Boesenbergia Rotunda vs Control in Asymptomatic COVID-19 [Andrographolide]

Estimated 3,060 patient andrographolide early treatment RCT with results not reported over 4 years after estimated completion.

Important missing comments or errors? Let us know.

Numthavaj et al., 30 May 2022, Single Blind Randomized Controlled Trial, Thailand, trial NCT05019326 (history). Contact: pawin.num@mahidol.ac.th.

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (7)27%

Hospitalization (1)50%

Progression (4)21%

Recovery (4)30%

Viral clearance (4)28%

RCTs (5)41%

Early (4)40%

Late (3)10%

00.511.5+

← Andrographolide
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

Most accessed treatments

Antiviral effects

Vitamins & Minerals

Host endosomal entry / trafficking

Dual-action mAbs

RdRp

Nasal & Oral Sprays / Rinses

Analgesics

Antiandrogens

Host targets and pathways

Inflammatory and immune modulation

Mpro (Gen 1)

Oxidative stress and cytoprotection

Lifestyles

TMPRSS2

Spike neutralization

Replication inhibition (target unresolved)

COVID-19 mAbs

Pleiotropic modulation

Attachment / entry inhibition

Mpro (Gen 2)

H1RAs

Nutrients and microbiome support

Host mAbs

IL-6 / IL-6R blockade

Physical and extracorporeal interventions

Natural products and extracts

Symptom management

Unconfirmed antiviral rationale

Lifestyle, behaviors, and exposure prevention

Other complication management

Mpro / 3CLpro

Host pyrimidine synthesis

Direct viral inactivation

Endothelial / vascular protection

Direct respiratory tract treatments

Other antibodies, proteins, peptides, cells, and RNA therapies

Secondary infection and coinfection management

Andrographis Paniculata vs Boesenbergia Rotunda vs Control in Asymptomatic COVID-19